At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...